Neurocrine Biosciences (NBIX) Tops Q3 EPS by 6c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $161.62 --0%
Revenue Growth %: +26.4%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +26.4%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $0.52, $0.06 better than the analyst estimate of $0.46. Revenue for the quarter came in at $151.8 million versus the consensus estimate of $151.83 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
- Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen
- RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
